Experiment 305: Pathophysiology of Mineral Loss During Space Flight by Cann, Christopher E. & Arnaud, Claude D.
(NASA-CR-188435) EXPERIMENT 305: N96-12610
PATHOPHYSIOLOGY OF MINERAL LOSS
DURING SPACE FLIGHT Final Report
(California Univ.) 34 p Unclas
G3/52 0072097
https://ntrs.nasa.gov/search.jsp?R=19960002602 2020-06-16T06:47:28+00:00Z
NASA Lyndon B. Johnson Space Center
„._. ,,,, ,00/oc Documentation Management Branch
NASA CR-188435 .
 Mail Code JM2
Houston, TX 77058
Mark For: Contract NAS 9-16227
Final Science Report
SLS-2
Experiment 305: Pathophysiology of Mineral Loss During Spaceflight
Claude D. Arnaud, M.D.
Christopher E. Cann, Ph.D.
University of California
San Francisco, CA 94143
O b j e c t i v e s
The objective of this SLS-2 experiment was to determine the pathophysiology
of mineral loss during space flight. This was to be accomplished by (1)
determining the concentrations of blood minerals and of calciotropic hormones
(parathyroid hormone-PTH, vitamin D metabolites) before, during, and after a 14
day shuttle flight, and (2) determining, by calcium kinetic analysis (using stable
calcium isotopes), the influence of space flight on intestinal calcium
absorption.
History of Project
Part (1) of this experiment was also performed on SLS-1. The results of that
investigation showed a dramatic increase of 30-40% in serum ionized calcium
by day 2 in space which persisted until day 8, with a rapid return to baseline
values (partially by day R+1, completely by R+6). Serum PTH showed a normal
adaptive response to this increased serum ionized calcium, with a rapid
decrease of 20-30% by day 2 persisting through day 8 and a slower return up to
normal levels by day R+6. 1,25(OH)2 vitamin D levels were reduced by day 8 in
flight as an expected response to the lowered serum PTH. When data for PTH (all
values were within the normal range) and serum Ca++ were plotted against each
other, the expected negative correlation was found, validating the results from
a biological perspective. The magnitude of the increase in serum calcium was
surprising, being at the low end of the range seen in hypercalcemia of
malignancy, and at a value which would be expected to cause some symptoms
such as nausea and general malaise. A second unexpected finding was the much
tighter negative correlation between PTH and Ca++ in males compared to
females, a difference which had not been noted before in the literature (but had
also not been investigated). The results of this SLS-1 study were consistent
with our hypothesis of a primary increase in bone resorption, or the release of
calcium from the bone, due to exposure to space flight, with a consequent
normal adaptive response from the parathyroid glands reducing PTH secretion
and a reduction in 1,25(OH)2 vitamin D production by the kidney.
The experiment performed on SLS-2 included both the endocrine response and
intestinal calcium absorption objectives. Due to some of the unexpected
findings from SLS-1, special care was taken for SLS-2 samples and
measurement procedures to ensure maximum confidence in the results.
Methodology
Sampling
Serum samples were obtained for the hormonal analyses at the prescribed
times, to correspond with those obtained for SLS-1, and all samples were
obtained. Oral and intravenous administration of the stable calcium isotope
tracers for the calcium absorption studies were accomplished as planned. There
were no apparent anomalies in tracer administration based on experiment logs,
and checks of the used and spare injection kits confirmed this. Blood samples
were obtained within minutes of the prescribed times for the tracer study. The
UMS functioned as expected, and the data for urine volumes have been provided
to E-305 from JSC with appropriate corrections for dilution and loss using the
LiCI and UMS inflight calibration data. These data were required in order to
make 24-hour urine pools for measuring collagen crosslink concentrations.
Preflight hormone blood draws and the calcium absorption study starting at L-
15 (actually L-19 because of the launch slip) went as planned, with all samples
obtained. Postflight, the hormone blood draws and urine collections were done
as planned. All samples were maintained frozen until analysis (in the case of
the serum specimens) or until aliquoting for further analysis (urine).
Tracer Administration
46Ca and 48Ca, stable isotopes of calcium, were used as tracers in this
study. The double-isotope method for determination of intestinal calcium
absorption was used, where an oral tracer is given (usually with a small
calcium load), followed some time later by an intravenous injection of the other
tracer. The ratio of the oral to intravenous tracer in the blood is taken as the
fraction of the calcium load absorbed. For this experiment, the double-isotope
study was done three times, once preflight (scheduled for L-15, done at L-19)
and twice inflight (FD3 and FD12). 46Qa was used as the IV tracer (0.35 mg 46Ca
as CaCl2 in 1 cc sterile saline), and 48Ca was given as an oral dose (2.50 mg
48Ca in a total of 20 mg elemental calcium as CaCOs). 48Ca was ingested on
awakening, followed by the 46Ca injection 60-70 minutes later. Blood samples
(6 ml, in serum separator tubes) were obtained just before the 46Ca injection
and at 4 hours, 10 hours, and 24 hours post-46Ca.
Mineral and Hormone Analysis
The measurement of Ca++ and PTH in serum specimens were done to
confirm the results obtained from SLS-1. In addition, because the serum ionized
calcium measurement is influenced by the pH of the sample, we also added a
measurement of serum pH. In order to maximize compatibility with our SLS-1
measurements, we elected to obtain an ionized calcium analysis instrument
from the same manufacturer as the one we used for SLS-1, but a newer model
which could also measure blood pH, Mg++, Na+, and K+. The instrument (Nova,
Model 8) uses the same selective ion electrode technology for Ca++
measurement as in the older model. At the time we made the measurements for
the SLS-2 samples, we arranged to have a service representative from the
company present with us in the laboratory in case any problems arose. Careful
analytical handling procedures were used, and samples were measured for each
astronaut as a set to maximize the internal consistency within each data set.
Prior to analysis of the samples from the astronauts, a set of experiments was
done using fresh and frozen/thawed serum from normal subjects, using all the
procedures planned for handling and analysis including NASA-provided blood
drawing tubes, to optimize the techniques and obtain baseline data.
Ca++ and pH were measured in a single sample at the same time, and PTH
was measured on the same day using an aliquot of the same sample. Serum tubes
were thawed rapidly and placed on ice, and opened in a glove box in a nitrogen
atmosphere to eliminate any possibility of COa contamination. The serum was
aspirated into a nitrogen-filled syringe which was then capped and allowed to
come to room temperature (22°C). Each serum sample was then aspirated
directly from the syringe into the ionized calcium analyzer through a stainless
steel probe without exposure to air. Duplicate measurements were made, using
180X each. Standards were measured routinely during the analysis. Intact PTH
was measured by the same sensitive and specific two-site radioimmunometric
assay used for SLS-1 samples. The remaining serum from each tube was
aliquoted and refrozen for analysis of the vitamin D metabolites.
Serum samples were also analyzed for osteocalcin, 25(OH)Ds and
1,25(OH)2D3 as specified. Total calcium values were obtained from data sharing
with E192. Urine deoxypyridinoline was measured with a commercial assay kit
(Metra Biosystems, Mountain View, CA).
Calcium Isotope Ratio Analysis
Calcium was isolated from samples by precipitation with oxalate and
washing in ammoniated oxalate buffer, followed by resolution with nitric acid,
and final purification on an ion-exchange column and extraction as calcium
rhenate, as preparation for analysis by thermal ionization mass spectrometry
(TIMS). 46Ca and 48Ca concentrations in the samples were determined by
reference to the isotope 44Ca. Precision of the measurements was 1.4% for
46Ca/44Ca and 0.067% for 48Ca/44Ca, as determined on reference samples of
NBS Standard Reference Material 915, Calcium Carbonate. 46Ca and 48Ca serum
concentrations were then calculated with reference to the administered dose
and expressed at each time point as percent administered dose per gram
circulating calcium in the blood (%ID/gm Ca). Intestinal calcium absorption
values were determined as the ratio of %ID 48Ca/gm Ca to %ID 46Ca/gm Ca.
Where possible, the values from the 4, 10 and 24 hour samples were averaged to
determine an effective fractional calcium absorption (a) for each subject.
Additional Serum Analyses
Based on the results we obtained from analysis of the serum samples with
the Nova, and the very low pH results we obtained in a number of the flight
samples, we enlisted the aid of an expert in acid-base metabolism at UCSF, Dr.
Anthony Sebastian, to discuss these results. At that time we had not analyzed
for serum osteocalcin and other measurements we planned to make, so we still
had the 6 ml draw serum samples frozen in our laboratory. In order to confirm
the Ca++ and pH results we had obtained from the selective ion electrode
method, we arranged with Dr. Sebastian to remeasure pH, as well as pOa and
pCOa in these samples using a blood gas analyzer. While we know that
measurement of blood gases on frozen samples can cause some systematic
errors, the samples we had were drawn to fill the tubes, had never been opened,
and were therefore essentially anaerobic. In addition, we expected that freezing
of the samples would only drive off blood gases, and therefore could only
increase serum pH if we lost COz rather than decrease pH. These samples were
analyzed at the General Clinical Research Center at UCSF, in Dr. Sebastian's
laboratories. Samples were processed about 6 at a time, taken at random from
the sample pool. They were thawed rapidly, and the serum was aspirated
anaerobically from the flight vacutainer into a syringe using an 18 gauge spinal
tap needle. During this process it was noted that some of the samples were
under positive pressure in the vacutainer, and while this was not quantified
directly (it was unexpected and we had no pressure measuring equipment
available), note was made of the approximate volume of gas forced into the
syringe when the needle pierced the top of the vacutainer. Serum samples were
then injected directly into a blood gas analyzer for measurement of pH, pCO2,
and pOa, and a second aliquot analyzed for total CO2 content using a different
method. Thus, at the end of the analysis, we had obtained serum pH and pCO2
each by two independent methods.
Resu l ts
Based on our SLS-1 results, we expected to see an increase in serum Ca++
and a corresponding decrease in PTH in flight. Figure 1 shows the change in
serum ionized calcium relative to baseline. Similar to the results we obtained
from SLS-1, there is a rapid and persistent elevation of the Ca++. Figure 2
shows the change in serum iPTH, again showing the decrease during spaceflight
in response to the increased serum calcium. Because the increase in Ca++ was
so rapid and large, we also evaluated the data for total plasma calcium provided
to us from E192 (we were unable to measure this in the serum becasue of the
presence of fibrin due to the serum clotting procedure used for our samples).
The data from E192 (Figure 3) also show a rise in total serum calcium (about 5%
compared to the 20% increase in Ca++), which also persists throughout the
mission. Thus, the possible influence of serum pH on our Ca++ measurements
(discussed below) may contribute to some of the increase we see, but the
increase in total calcium seen in a completely different data set confirms that
the PTH response we see is of biological significance. As we did in SLS-1, we
did a correlation of serum iPTH vs Ca++ to document the expected negative
correlation between these two parameters in the subject population. These
results are shown in Figure 4, where this negative correlation was seen for 3
out of 4 subjects. Of note in this SLS-2 experiment, the preflight baseline
values of PTH were lower in this population compared to the SLS-1 subjects,
and this probably contributed to the smaller decrease inflight when compared to
the SLS-1 results.
Figures 5 and 6 show the results for measurement of serum 25(OH)D3 and
1,25(OH)2D3. The level of 25(OH)D3 increases during flight by 15-20%. There is
no biological explanation for this to occur, as this metabolite is in excess in the
serum as a substrate for 1,25(OH)2D3. However, the increase may be related
simply to the decrease in plasma volume seen in the astronauts, because the
25(OH)Ds concentration in the serum is not tightly regulated, so it would not be
excreted preferentially. Normal preflight serum 1,25(OH)2D3 values are very
consistent and show about a 30-40% decrease by FD6, similar to the decrease
seen in SLS-1. This level persists until day 12, but appears to begin to recover
toward the end of the flight. The slight increase on R+1 was also seen on SLS-1.
Serum osteocalcin concentration is shown in Figure 7. Values for this
bone-specific protein decline rapidly in flight and remain depressed.
Osteocalcin concentration in serum is often taken as an indicator of bone
formation, so this could signify a decrease in bone formation during spaceflight.
However, serum osteocalcin is also depressed by cortisol, so a stress response
cannot be ruled out in spaceflight.
Urine deoxypyridinoline results are shown in Figure 8. The individual data
are graphed to show the differences we noted in 3 subjects compared to the
fourth. During the preflight and inflight periods, there are peaks in DPD
excretion which correspond to days when E192 experiments were done. It is not
clear what factors in that experiment could have increased DPD excretion.
However, when these high data points are eliminated and the data reanalyzed,
we see the expected increase in DPD with flight (Figure 9). The increase is
about 40%, climbing rapidly from day 4 to day 8 and remaining at that level
throughout the flight and up to 2 weeks postflight. This is the first evidence
that there is a dramatic increase in bone resorption in humans during
spaceflight, and supports our original hypothesis for this experiment.
Fractional intestinal calcium absorption was measured as the ratio of
specific activity of orally-administered 48Ca (in a 20 mg Ca load, fasting) to
that of intravenously administered 46Ca, given about 1 hour later. The preflight
study was done on L-19, and the inflight studies done on FD3 and FD12. In two
samples (one preflight, one inflight) the isotopic ratio of 46Ca was inordinately
high, suggesting contamination of the blood sample from residual isotope at the
injection site, and these samples were eliminated from the analysis. On FD3,
one crewmember had unmeasurable concentrations of 48Ca from the oral dose,
even though the 46Ca injection was done. While confirmation of the 46Ca tracer
injections was possible because the used injectors were returned, the package
with the 48Ca capsules was not returned so no confirmation could be made that
the crewmember took the capsule. The sensitivity of the 48Ca analysis is such
that if there was any absorption (even as low as 1-2%) it would be seen. Thus, it
was assumed that the crewmember did not take the dose, and these data were
eliminated from the analysis.
The data for fractional absorption (a) are shown in Figure 10. The
preflight mean of 0.58 is higher than the normal true fractional absorption of
calcium (0.3-0.5), but it is expected because of the design of the study, giving a
small calcium load orally in the fasted condition. By FD3, the absorption
fraction had decreased to about 0.4 (a 33% decrease), and the 3 crew for which
data were available all showed about the same response. On FD12, two
crewmembers showed one pattern, a very low fractional absorption, while the
other two crew had a value higher than preflight. On further inspection of the
data, it was found that the male crew had the high values and the female crew
the lower values, so these results were plotted separately on Figure 10. A
representative 46Ca specific activity curve is shown in Figure 11, where the
peak values preflight and for the two inflight studies represent the 4 hour data
points. There is a suggestion of an increase in peak specific activity during
flight, which may indicate a decrease in the size of the rapidly exchangeable
calcium pool (blood, soft tissues).
Our primary serum analyses had identified an unexplained decrease in
serum pH which could affect our measurement of serum Ca++. Therefore, we
undertook the additional analyses outlined previously, with the aid of Dr. A.
Sebastian at UCSF. The results of measurement of blood CO2 are shown in Figure
12, and pH in Figure 13. These data confirm that the decrease in serum pH seen
with the Nova specific ion Ca++/pH analyzer was due to an increase in the CO2
content in the blood, and not another factor such as lactic acid. This decreased
oH was onlv seen in fliaht samoles. We have been unable to reoroduce this
and using flight equipment to process the blood samples using the identical
protocol used in flight. In addition, the preflight and postflight samples from
the astronauts were processed using the flight protocol (clotting in the
refrigerator, centrifuging in a non-refrigerated centrifuge, and immediately
freezing the whole tube), and did not show this increase in CO2. We have thus
been unable to come up with a technical explanation for the increased CC>2 in our
frozen blood samples. Some hypotheses for a physiological explanation will be
considered in the discussion.
Discussion
The results we have obtained from SLS-1 and SLS-2 are consistent with
our original hypothesis that increased release of calcium from bone would cause
an increase in serum ionized calcium, and a subsequent adaptive decrease in the
secretion of parathyroid hormone into the blood. Our results from SLS-1 were
somewhat puzzling in that we did not expect to see such a rapid rise of Ca++,
nor one of such magnitude; instead we expected that the rise would be more
gradual with an increase in osteoclastic recruitment leading to the increased
resorption within a few days to a week of microgravity. We thus hypothesized
that some other mechanism, such as an opening of the bone-blood barrier, could
be leading to the early dramatic increase in Ca++. Our observations from SLS-2
provide another possible mechanism for this increase, a direct effect of reduced
serum pH on the equilibrium between free and protein-bound calcium. This
effect is clearly due to an increase in the serum CO2 in the samples we received
from flight. We cannot rule out a technical source for this increased CO2, but we
cannot reproduce it in the laboratory on earth. Independent of any possible
influences of pH on Ca++, data from E192 show that serum total calcium is also
increased, which supports our results showing an adaptive decrease in PTH
during flight.
Our initial hypothesis that bone resorption increases early in flight and
causes a rise in serum calcium is directly supported by the urine DPD results.
By FD5, the output of this collagen crosslink starts to increase, to a new
plateau value about 40% above baseline. This is consistent with the time needed
to recruit new osteoclasts from the bone marrow and increase the number of
bone resorbing sites. The fact that serum calcium rises earlier, with an
adaptive decrease in PTH by day 2 means that there may be other factors
influencing serum Ca++, independent of the increase in bone resorption. The
existence of an early, alternative mechanism to increase serum Ca++ in no way
diminishes the role of increased bone resorption a few days into flight, and the
possible use of antiresorptive drugs in long-term flights is still a valid
consideration. However, because the increase in blood calcium occurs earlier
and sets off the adaptive hormonal regulatory processes, it is important to
identify this other mechanism as well. Serum osteocalcin, generally considered
to be a marker for bone formation, is decreased early in flight. If it is true that
bone formation, or mineralization, is decreased, then this could be another
mechanism contributing to the increased serum calcium as its normal movement
into bone from the serum is reduced.
The endocrine regulation of calcium metabolism in spaceflight appears to
occur normally. PTH is decreased in response to the increased serum calcium,
and a decrease in 1,25(OH)2D3 presumably secondary to decreased PTH occurs by
day 6 and persists for the length of the mission. There is the expected decrease
in intestinal calcium absorption, although it was not expected to decrease as
early as FD3-4. In addition, the increase in calcium absorption seen in the two
male crew by FD12 was unexpected, especially because there was no correlation
for the crew as a whole between serum 1,25(OH)2D3 and the fractional calcium
absorption. It is possible that other mechanisms influence calcium absorption
as well, such as changes in intestinal motility due to the lack of gravity.
The gender differences noted in SLS-1 and now in SLS-2 also deserve
further investigation. With the expected negative correlation between PTH and
Ca++ only clearly apparent in males, and a significant difference in intestinal
absorption late in the flight, there appear to be factors other than the ones we
associate classically with calcium and bone homeostasis. The sex hormones are
a clear starting point, as might be responses to stress.
The increased CO2 we found in our blood samples from flight is puzzling,
because we cannot reproduce it in the laboratory. While we cannot rule out a
technical explanation, we may also consider some physiological explanations
why this may occur. First, it is known that in microgravity there is increased
blood in the periphery, and it is possible that there is considerable stasis in the
capillary bed. If this was the case, the residence time of blood in the capillaries
could be increased, allowing more COa to diffuse into the blood and decreasing
its pH. Because we obtain blood from venous puncture, it may be the case that
this blood contains more CO2 than central blood because of its increased
capillary residence time. It may not show up in increased lung output of CO2
because the peripheral blood is a small fraction of the total circulating blood,
and this fraction may even decrease in space. A second possibility may be that
the red cells are capable of carrying more CO2 while in microgravity, so that
even if the central blood contained more CO2 it would not necessarily be
transported across the lung membranes and exhaled. Both these hypotheses
could be tested in microgravity. Before doing so, however, all technical
explanations should be ruled out, and this necessitates measuring the blood
gases immediately after obtaining a blood sample in space using a blood gas
analyzer. Portable units are available and should be able to be flight qualified
for this purpose.
Summary
Our hypothesis that increased bone resorption with exposure to
microgravity causes an increase in serum calcium and that the body will try to
return the serum calcium to normal through adaptive processes is supported by
our results from the SLS-1 and SLS-2 missions. Increased serum calcium,
decreased serum PTH, a later decrease in serum 1,25(OH)2D3, and decreased
intestinal calcium absorption all occur. Urine deoxypyridinoline rises after 4
days of flight and remains elevated, consistent with recruitment of osteoclasts
and the formation of new bone resorbing sites. Serum osteocalcin is decreased,
a possible indicator of decreased bone formation.
The magnitude and timing of the increase in serum Ca++ indicate that
processes other than bone resorption also influence the serum calcium. The rise
in serum calcium occurs by day 2 along with the adaptive decrease in serum
PTH, while the evidence for bone resorption does not come until several days
later. This could be due to a direct release of calcium from the bone fluid
compartment, or from other stores of rapidly exchangeable calcium in the body
(eg mitochondria); it could also be influenced by a decrease in the rate of
mineralization of bone while resorption and intestinal absorption are still at
normal levels.
Gender differences in serum calcium regulation occur in spaceflight, and
these should be considered further in the design and implementation of further
studies of calcium and bone metabolism in spaceflight.
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Figure 1. The rise in serum Ca++ relative to baseline values is about 25% and
persists throughout the flight. This is virtually identical to the results seen for
SLS-1.
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Figure 2. Depression of serum iPTH occurs early in flight and persists. Rise on
FD6 is unexplained, but it should be noted that the baseline values for this
population are at the low end of the normal range, so the result may be related
simply to the variation in the data.
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Figure 3. Results from E192 data sharing show a rise in total serum calcium
after the first couple of days which persists throughout the mission, and
returning back to normal quickly upon recovery.
Correlations for PTH vs Ca++
Individual Crewmembers
Ca++
Figure 4. The individual correlations between the serum Ca++ and PTH within
the normal range for the individual crew are shown. The correlations were
significant for 3 of the 4 crew, similar to the results seen on SLS-1. These
correlations indicate that the results seen for Ca++ are not an artifact,
otherwise the normal depression of PTH should not occur.
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Figure 5. Change in serum 25-hydroxyvitamin-D3 with spaceflight. The 15-20%
rise may be related to reductions in plasma volume.
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Figure 6. Serum 1,25-dihydroxyvitamin-D3 relative to preflight average values
(pg/ml). Normal preflight values are very consistent and show about a 30-40%
decrease by FD6, similar to the decrease seen in SLS-1. This level persists until
day 12, but appears to begin to recover toward the end of the flight. The slight
increase on R+1 was also seen on SLS-1.
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Figure 7. Serum osteocalcin relative to baseline values. Decrease by FD2
persists throughout flight, indicating possible decrease in bone formation.
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Individual data for Urine DPD
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Figure 8. Individual data for urinary deoxypyridinoline. Note that in 3 subjects
there are peaks in the data on the days when other experiments were being done
for E192.
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Figure 9. Urine deoxypyridinoline in one crewmember. The preflight baseline is
stable. Within 5 days after launch the value increases about 40% and remains at
this level throughout the flight and up to 2 weeks postflight.
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Figure 10. Fractional calcium absorption preflight and on FD3 and FD12. Data for
FD12 are divided into male and female crew because of large differences noted.
No such differences were noted preflight or on FD3.
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Figure 11. Specific activity for 46Ca following intravenous administration. Data
shown from one subject for illustration. Apparent increase in peak values could
be related to a shrinking of the miscible calcium pool (serum, soft tissues).
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Figure 12. Blood CO2 measurements relative to preflight values. Virtually all
flight samples have elevated concentration of CO2, as determined by two
different methods. This corresponds to the lowered pH seen in these samples.
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Figure 13. Serum pH, as measured by blood gas analyzer system, confirming
results obtained using the Nova specific ion Ca++/pH measurement system. Very
low values could not be reproduced in the laboratory even under identical blood
processing and handling conditions.
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Co-Princ-ipal I n v e s t i g a t o r s - -
This report supplements the final-report submitted previously for
E305 for the SLS-1 mission. It contains the previously reported material,
but in addition it contains results from the analysis of urine obtained by
special request, provided by Dr. Carolyn Huntoon from residual samples
from E192. The methodology, results, and discussion sections have been -
revised to include these analyses in the overall mission results.
Ob jec t i ve
The objective of this1 SLS-1 experiment was to determine the
pathophysiology of mineral loss during space flight. This was to be
accomplished by (1) determining the concentrations -of blood minerals and
of calciotropic hormones (parathyroid hormone, vitamin D metabolites)
before, during and after a 7-10 day shuttle flight and (2) determining, by
calcium kinetic analysis (using stable calcium isotopes), the influence of
space flight on calcium absorption and bone turnover.
History of Project
Due to priority considerations, part -(2) of-the experimental package
was deleted from the composite of SLS-1 experiments, leaving part (1)-
which •involved simple blood sampling at L-15, L-7, L-2, FD 2, FD 8, R+1
and R+6. Both parts (1) and (2) will be performed on SLS-2.
At this writing, all serum "collected during SLS-t for E305 has been
consumed in the measurement of ionized calcium, immunoreactive intact
parathyroid hormone, 25 hydroxyvitamin D and 1,25 dihydroxyvitamin D.
In order to further interpret the preliminary results we found in the
serum samples (detailed below), we requested and obtained small amounts
of urine which had been collected for other experiments (E192) and for
which all other analyses had been completed. The volumes of urine
obtained were small, and samples were not available for "all time points;
however, enough samples were analyzed to provide useful information to
help in the interpretation of the serum results we obtained.
f
Methodology -• . . -
Serum ionized calcium was measured by selective ion electrode,
intact immunoreactive parathyroid hormone (intact PTH) by a sensitive
and specific -two-site radioimmuhdrnetric- assay, and-25 hydro-xyvitamin D
and" 1,25 hydroxyvitamin D by receptor binding assays. Thre full
complement of 28 serum" intact PTH measurements were performed but
the volumes remaining were inadequate to measure ionized calcium in two
serum samples (MS3 for R+1 and PS2 for FD 8), 25 hydroxyvitamin D in
two serum samples (MS1 for L-2 and FD 8), and 1,25 dihydroxyvitamin D in-
one serum sample (MS1 for R+1). In general, the consistency with which
blood was collected was surprisingly good, but the quantity of serum,
recovered was considerably less than the 2.0 ml that was anticipated, i.e.
approximately 1.5 ml in most cases.
The volume of most urine samples obtained was small (100-200 u.l),
so the analyses we could do were limited. Our primary goal was to
determine the concentrations of the collagen crosslinks pyridinoline (PYD)
and deoxypyridinoline (DPD) released during bone resorption. With the
urine volumes available, we were only able to measure the concentrations
of PYD, using a specific immunometric assay. Samples were obtained and
analyzed from individual urine voids, from preflight, inflight, and
postflight voids. 80-100 samples per crewmember were obtained. Where
possible, 24-hour analyses were done by mathematically pooling the
results from the individual voids.
Resu l ts
We expected that among the astronaut crew the biologically normal
negative correlation between serum ionized calcium and intact PTH would
be exhibited because we expected that any changes due to space flight
would be in the normal physiological range of responses. We therefore
performed a statistical analysis of the relationship of these variables
across all .measurements in all subjects. The correlation coefficient for
this relationship was negative (0.52) and significant (p < 0.01) as
expected (Figure 1). Based on this analysis, we concluded that the
responses of the crew to perturbations in extracellular calcium
homeostasis reflected appropriate physiologic adaptive responses.
t .,. Serum ionized, calcium increased dramatical^ orr FD 2 to levels 40%
above control, levels that are -normally considered to be representative of
severe hypercalcemia (Figure 2). By FD 8, serum iofijzed calcium levels
were still 35% above normal, indicating that clinically significant
hypercalcemia was maintained-throughout the flight. Mean serum intact
PTH declined appropriately to about 50% of control throughout the flight, a
finding that biologically validates the increase in serum ionized calcium
and discounts the possibility that PTH is responsible for the
hypercalcemia.. Serum 'calcium-returned toward control values oh ~R+1 and
was no different from control on R+6. Serum intact PTH returned more
slowly to "control values. .-.
Serum 1,25 dihydroxyvitamin D (Figure 2) was within the range of
control on FD 2 but had declined by 40% on FD 8. Postflight, 1,25
dihydroxyvitamin D values increased to 25% above control "on R+1 and then
decreased to control values by R+6. No changes were observed in serum 25
hydroxyvitamin" D levels inflight or postflight.
We sought cause for the relatively low correlation coefficient
between serum ionized calcium and intact PTH by examining the
correlation coefficients for these variables in individual subjects (Figure
3). MS1 and PS1 fit one pattern with a correction coefficient of 0.8,
while MS3 and PS2 exhibited a much lower correlation (0,3) (Figure 4), On
decoding the data, we found that the male crew members showed the
highest correlation (Figure 5). This is an unexpected finding that deserves
further investigation, especially relative to the possible influence of
reproductive hormones on calcium metabolism in space flight. Preliminary
assessment of sex differences in the responses of the vitamin D
metabolites show no correlations.
- Results for the analyses of PYD in urine were mixed, with some crew
showing the .expected increase of PYD in urine from increased bone
resorption'and others not. This also appeared to be related to gender.
Results from one female and one male crewmember are shown in Figure 6
for morning fasted values and Jn Figure 7 for total daily output. Figure 8
shows the comparison of the first morning urine void and the total 24 hour
PYD output relative to urinary, creatinine. During flight, the normal
nocturnal increase in PYD is suppressed.
Discuss ion
The data we report herein support our hypothesis concerning the
bone and mineral abnormalities caused by space flight. The data suggest
that,-our measurements are biologically valid, that they qualitatively
-parallel those observed in immobilization osteoporosis except that
hypercalcemia is more severe during acute microgravlty exposure, and
that they are consistent with increased bone resorption playing ,,a major
. role in the pathogenesis of mineral loss during space flight. Bas.ed on
these results, anti-resorptive drugs could be useful in preventing the bone
loss of space flight.
The evidence from these data" that exposure to microgravity causes
increased bone resorption with consequent hypercalcemia and decreased
serum is suggestive. The magnitude of the increase in serum ionized-
calcium in the presence of decreased 1,25-dihydroxyvitamin D suggests
that the calcium is being released from bone rather than coming from an
increase in intestinal calcium absorption. We expect to test this directly
with experiments on SLS-2. However, because we were unable to measure
total serum calcium in these samples (due to low volumes and the
presence of fibrin in the serum), and the evidence from other experiments
(E192) for an increase in total calcium is limited, we cannot rule out that
the increase in ionized calcium is due to a change in the free to bound
fraction of calcium in the serum.. This could be due to a change in serum
protein concentration or a change in serum pH altering the free to bound
ratio. • -
The increase in total urinary PYD during flight and the recovery
period is consistent with the hypothesis that there is increased
osteoclastic resorption during spaceflight which persists after return to
1-g. When normalized to urinary creatinine, the 24 hour PYD output also
rises inflight in females, similar to the increase in total PYD seen in
males, although the gender differences, similar to those seen in the serum
results, need to be clarified. In terrestrial clinical studies, the first
morning urine PYD is higher because of the nocturnal increase in bone
resorption", and so this void is often used-for routine clinical diagnosis
because of greater measurement sensitivity and ease of collection. We
expected to see this increase-in these studies, and during the .preflight .
period this was the case, with a 65% increase in the first morning
samples. This appeared to be the case for the postf!4ght samples as well,
but the number of postflight samples available was small. Inflight, this
nocturnal increase was eliminated, with AM concentrations 98±1-5% of 24
hour levels. This was an unexpected finding, and- clearly warrants further
study in the context of the effects of spaceflight on diurnal variations in
bone turnover.
All our results and interpretation of the PYD analyses must be done
in. the context of possible nonspecificity. Pyridinoline crosslinks are
'produced when collagen is formed, and they are released and excreted
when"collagen is broken down. In bone, this occurs5 during osteoclastic
resorption of the bone matrix. For routine clinical studies, PYD excretion
is a relatively sensitive marker for bone turnover, because any. changes in
PYD excretion are normally due to changes in bone resorption. In
spaceflight, however, there is also breakdown of collagen from other
sources such as muscle, and the elevated PYD in the urine may come partly
from these other sources. Deoxypyridinoline is specific for bone collagen;
but the volumes of urine available to us did not permit DPD analysis. We
expect to do this with- urine samples-from SLS-2 to confirm our PYD
findings from SLS-1-. -
Summary
The results of this study of calcium regulation and bone metabolism
during SLS-1 are consistent with our hypothesis that spaceflight causes a
primary increase in bone resorption, leading to normal .adaptive hormonal
responses to reduce the increased serum calcium. These adaptive
responses are not pathologic, but can be predicted based on our model of
calcium homeostasis. We saw an early and sustained increase in serum
ionized calcium with a rapid decrease in serum parathyroid hormone in
response. Both these parameters normalized upon return to 1-g, with the
PTH response lagging the ionized calcium. 1,25-dihydroxyvitamin D
concentrations were reduced by 6 days into flight, probably from reduced
synthesis due to the reduced serum PTH, an effect which should reduce
intestinal calcium absorption as part of the adaptive response to reduce
serum calcium. This parameter also normalized on return to 1-g. Urinary
pyridinoline output increased during spaceflight, most likely due to an
increase in bone resorption. These values did not return to normal by day 6
postflight, but limited, data are available. " - _
Several findings were unexpected.
The magnitude of tha increase in serum ionized calcium was close to
that seen in hypercalcemia of malignancy, but apparently was not
accompanied by a similar increase in total serum calcium (based on data
from E192). This suggests that factors other than simple bone resorption
may come into play, such as variations in serum proteins or serum pH
which will affect the ratio of free to bound calcium in the blood.
As a group, the blood samples from the crew showed the expected
negative correlation between serum ionized calcium and PTH, with a
cc//elation coefficient of about -0.5. This is similar to that.seen in other
population studies and validated the measurements as being biologically
appropriate. Further inspection of these data, however, revealed individual
differences, and these were traced to a gender difference; male,s had a
correlation of about -0.8 between PTH and Ca++, while there was no
correlation for females. This unexpected difference may be due to-the
influence of sex steroids, but this could not be tested with the small
volumes of serum available.
Gender differences were also noted in the results for urinary PYD,
with both-sexes-showing a rise with spacefligrvt, but which was only"
apparent Jn females when data were normalized to urine creatinine.
However, the most striking finding in the PYD results was the suppression
of the normal nocturnal rise in PYD excretion, from the normal 65% excess
relative to creatinine to no excess. This suggests that spaceflight may
affect the diurnal variations in" bone turnover.
While in general the.results of this study support our hypothesis of a
primary increase in bone resorption during spaceflight, the unexpected
findings suggest that this may not be the only process affecting calcium
and bone metabolism in microgravity. The gender differences suggest that
sex steroids may have a significant influence, not- unexpected- given the
existence of such an influence on earth, and this can be investigated
further with appropriate attention to these hormones. Clearly the
disproportionate magnitude of the ionized calcium increase needs to be
investigated, with special attention to those other moieties known to
affect it. The suppression of the nocturnal elevation of PYD excretion
must be confirmed, preferably using the more specific bone marker DPD,
and hypotheses put forth to try to explain this. We will attempt to explore
these unexpected findings during SLS-2 as possible within the constraints
o f that experiment. ' - . . - •
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Figure 6. Total PYD in first morning fasted urine forterna'e (top) and male
(bottom) crewmembers. There are no significant differences noted inflight from
preflight values. ' ; . . " .
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Figure 7. Total PYD output per day in female (top) and male (bottom)
crewmembers.-While female crew show little effect of spacef light on total" PYD
dutput, male crew shows significant increase.with flight, as .expected if bone
resorotion is increased. " J*
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Figure 8. Urine PYD/Cr ratios in female (top) and male (bottom) crewmembers
for first morning void and 24 hour pooled urines. Note that inflight, ratios are
very similar for first morning and whole day collections,, while preflight and
poslflight the -expected nocturnal increase is seen.
O
Q
Ratio of Urine PYD in
First Morning vs 24 Hour
3 r
B male
• female
Q D
B*
- 3 0 20 1 0 0
DAYS
1 0 2 0
Figure 9. Ratio of PYD output in first morning void compared to 24 hour pooled
urine collection. The normal 50-80% increase seen preflight is eliminated
during the flight period.
